Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
24 Maio 2023 - 9:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene
editing company developing ARCUS®-based in vivo gene editing and ex
vivo allogeneic CAR T therapies, today announced that the Company
will participate in the Stifel Genetic Medicines Day taking place
May 30, 2023.
Details for the virtual fireside chat are as follows:
Date: Tuesday, May 30, 2023 Time: 2:25 PM ET
The fireside chat will be available via a live webcast
accessible on Precision’s website in the Investors section under
Events & Presentations on May 30, 2023:
https://investor.precisionbiosciences.com/events-and-presentations.
An archived replay will be available for approximately 30 days
following the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
precise and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the Company’s pipeline consists of several in vivo gene
editing candidates designed to cure genetic and infectious diseases
where no adequate treatments exist and multiple ex vivo clinical
candidates. For more information about Precision BioSciences,
please visit www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230524005508/en/
Investor and Media Contact: Mei Burris Director, Investor
Relations & Finance Mei.burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024